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Mammalian brain connectivity requires the coordinated production
and migration of billions of neurons and the formation of axons and
dendrites. TheLKB1/Par4kinase is requiredforaxon formationduring
cortical development in vivo partially through its ability to activate
SAD-A/B kinases. LKB1 is a master kinase phosphorylating and
activating at least 11 other serine/threonine kinases including the
metabolic sensor AMP-activated protein kinase (AMPK), which
defines this branch of the kinome. A recent study using a gene-trap
allele of the β1 regulatory subunit of AMPK suggested that AMPK
catalytic activity is required for proper brain development includ-
ing neurogenesis and neuronal survival. We used a genetic loss-
of-function approach producing AMPKα1/α2-null cortical neurons
todemonstrate thatAMPKcatalytic activity is not required for cortical
neurogenesis,neuronalmigration, polarization,or survival.However,
we found that application ofmetformin or AICAR, potent AMPK acti-
vators, inhibit axogenesis and axon growth in an AMPK-dependent
manner.We show that inhibition of axongrowthmediated byAMPK
overactivation requires TSC1/2-mediated inhibition of the mamma-
lian target of rapamycin (mTOR) signaling pathway. Our results dem-
onstrate that AMPK catalytic activity is not required for early neural
development in vivo but its overactivation during metabolic stress
impairs neuronal polarization in a mTOR-dependent manner.
AMP-activated kinase (AMPK) is a heterotrimeric serine/threonine protein kinase composed of one catalytic subunit
(encoded by α1 or α2 genes in mammals) and two regulatory
subunits β and γ (encoded by β1 or β2 genes and γ1, γ2, or γ3 genes,
respectively) (1–3). AMPK is an important metabolic sensor, ac-
tivated by various forms of metabolic stress including low ATP:
AMP ratios. AMPK has been implicated in a range of cell bi-
ological functions including cell polarity, autophagy, apoptosis,
and cell migration (2–9). A recent study (10) suggested that the
regulatory subunit, AMPKβ1, is critical for normal neurogenesis,
neuronal differentiation, and neuronal survival during cortical
development. However, to date there is no published evidence
reporting the consequence of a genetic loss of function for the
catalytic activity of mammalian AMPK in the mammalian nervous
system. To assess the role of AMPKα during cortical development,
we used transgenic mice that were ubiquitously inactivated for the
AMPKα1 gene (AMPKα1−/−) (11) and conditionally inactivated
for AMPKα2 (AMPKα2F/F) (12, 13). AMPKα2 was selectively
deleted using the Emx1Cre mouse line, which induces re-
combination only in dorsal telencephalic progenitors giving rise to
all pyramidal projection neurons in the cortex, but not in ventral
telencephalon-derived cortical GABAergic interneurons, which
constitutes ∼25% of all cortical neurons (14). Surprisingly, we
found no obvious defect of neurogenesis, neuronalmigration, axon
formation, or neuronal survival in AMPKα1/2-null cortex com-
pared with control mice. On the basis of the profound differences
between the phenotypes observed in LKB1-null neurons (15, 16)
and the AMPK-null neurons (present study), we conclude that (i)
under normal conditions, AMPK is not required for neurogenesis,
neuronal differentiation, or neuronal survival in vivo; (ii) LKB1
function does not require AMPK catalytic activity to control
neuronal polarization and survival but that (iii) metabolic stress
inhibits axon formation during neuronal polarization as well as
axon growth in an AMPK- and mammalian target of rapamycin
(mTOR)-dependent manner.
Results
Genetic Loss-of-Function Approach Deleting AMPKα1/α2 Catalytic
Subunits in Cortical Neurons. We first documented the pattern of
expression of AMPKα1 [Mouse Genome Informatics (MGI):
Prkaa1] and AMPKα2 (MGI: Prkaa2) during cortical de-
velopment using RT-PCR (Fig. S1A) and found that both genes
are expressed throughout embryonic and postnatal development
and in the adult cortex. Interestingly, whereas mRNA expression
levels of AMPKα1 seem rather constant at all stages examined,
levels of AMPKα2 seem more tightly regulated developmentally
with low levels at embryonic day (E)15.5 and peak levels during
the first week of postnatal development. We confirmed these
results at the protein level using an antibody that recognizes both
total AMPKα1 and α2 (Fig. S1B). Interestingly, the level of
AMPK activation measured by detection of phosphoT172-
AMPK is high from E15.5 to postnatal day 1 (P1) but decreases
significantly during postnatal development until adulthood (Fig.
S1B). Several well-characterized substrates of AMPK such as
ACC and GABAB receptor 2 display drastically different tem-
poral patterns of phosphorylation. ACC phosphorylation is high
from E15 to P7 but low after P15 and in adult cortex, whereas
GABAB R2 phosphorylation on S783, which is entirely mediated
by AMPK (Fig. S1F), is almost undetectable from E15 to P1.
However, GABAB R2 phosphorylation increases progressively
from P7 to adulthood, nicely correlating with synaptogenesis in
the cortex. Finally, to circumvent the mixed nature of cell types
encountered in the cortex at different stages (neurons, astrocytes,
oligodendrocytes, etc.) we placed E18 cortical progenitors in
culture conditions that strongly enrich for postmitotic pyramidal
neurons with very limited astrocytes and oligodendrocytes. This
analysis confirms that AMPK is expressed and activated rather
constantly during early neuronal differentiation in vitro but its level
of activation decreases sharply after 5 d in vitro (div) (Fig. S1C),
mimicking observations at early postnatal stages in vivo (after P1;
Fig. S1B). Taken together, the expression data show that AMPK
is expressed in cortical neurons throughout development and in
adulthood, but that its activation and ability to phosphorylate
downstream targets is tightly regulated temporally.
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We generated a cortex-specific genetic ablation of AMPK
catalytic activity by crossing a constitutive AMPKα1 knockout
mouse with a mouse carrying an AMPKα2F conditional allele.
Recombination of the AMPKα2F allele specifically in cortical
progenitors giving rise to all pyramidal neurons was achieved
by crossing with an Emx1Cre mouse (14). We next validated that
our genetic approach by harvesting cortical lysates from P3
Emx1Cre/+; AMPKα1−/−α2F/F mice (hereafter referred to as
AMPKα-double conditional knockout, DcKO). Western blot
analysis shows that total AMPKα (1 + 2) protein expression
level is reduced by 70% compared with control littermates
(Emx1Cre/+; AMPKα1+/−α2F/F or Emx1Cre; AMPKα1+/+α2F/F,
n = 3) (Fig. S1D). To evaluate protein levels without contribu-
tion from astrocytes, cortical interneurons, and blood vessels,
we dissociated cultures of E15 dorsal telencephalic progenitors
for 4 div. In these conditions, more than 90% of cells in culture
are postmitotic glutamatergic pyramidal neurons and the cul-
tures are almost completely devoid of radial glial progenitors
or astrocytes when cultured in serum-free conditions (17, 18).
Under these culture conditions, we have enriched for postmitotic
pyramidal cortical neurons where Emx1Cre should efficiently
induce Cre-recombination and our Western blot analysis reveals
a complete loss of AMPKα protein expression in the AMPKα-
DcKO compared with control mice (Fig. S1E). To confirm the in
vivo ablation of the catalytic activity of AMPK, we used phos-
pho-specific antibodies detecting two previously characterized
AMPK protein substrates: serine 783 of the GABAB receptor 2
(19) and retinoblastoma (Rb) protein on serines 807 and 811
(10). Phosphorylation of both of these proteins is abolished in
the P3 cortex of AMPKα-DcKO compared with control mice
(Fig. S1 F and G). These results demonstrate that our genetic
approach generates a complete loss of AMPK catalytic activity in
cortical pyramidal neurons in vivo.
AMPK Catalytic Activity Is Not Required for Proper Cortical
Development in Vivo. AMPKα-DcKO mice are viable at birth
and several individuals survived until adulthood. This allowed
us to examine several aspects of cortical development at early
postnatal stages. At P3, analysis of the expression of layer-specific
markers such as CTIP2 (layer 5 marker), Cux1 (layer 2–4 marker)
and Tbr1 (layer 6a marker) revealed no difference in layer for-
mation between the AMPKα-DcKO (Fig. 1A′–H′) compared with
control littermates (Fig. 1A–H). This strongly argues that AMPKα
is not required for proper neurogenesis and neuronal migration
in vivo. Loss of function of LKB1 (a major activator of AMPK
through its ability to phosphorylate T172) and loss of function
of AMPKβ1 were both reported to lead to significant levels of
neuronal apoptosis in vivo (10, 15). In contrast, we found that
neuronal apoptosis, as measured by the number of activated cas-
pase 3-positive cells, is low in AMPKα-DcKO (Fig. 1 I′–L′) and
not different from control littermates (Fig. 1 I–L). Finally, axon-
specific (Tau1) and dendrite-specific (MAP2) marker analysis
revealed no difference between the AMPKα-DcKO (Fig. 1M′–P′)
and control littermates (Fig. 1 M–P), suggesting no gross abnor-
malities in neuronal polarization and axon–dendrite growth. This
contrasts with the phenotype observed in LKB1 cKO as well as in
two other effectors of LKB1, namely SAD-A/B kinase DKOmice,
where cortical pyramidal neurons do not form axons (15, 20).
To directly visualize neuronal morphology and axon–dendrite
polarization, we used two alternative approaches. First we per-
formed ex utero cortical electroporation (EUCE) on AMPKα1−/−;
AMPKα2F/F embryos at E15 using plasmids expressing EGFP
(Fig. 2 A and A′) or Cre recombinase-internal ribosome entry
site (IRES)-EGFP (Fig. 2 B and B′) to simultaneously visualize
neuronal morphology and achieve Cre-mediated recombination
of AMPKα2. Following organotypic slice culture for 5 d ex vivo
(DEV), this technique allows monitoring of both neuronal mi-
gration and axon formation of cortical progenitors from the
ventricular zone (VZ) to their final position in the cortical plate
(CP) (15, 18). Because the progenitors electroporated at E15
give rise primarily to callosally projecting pyramidal neurons
destined to layer 2–3, most axons emerging from GFP-expressing
neurons (red arrow in Fig. 2A) project toward the midline
(arrowheads in Fig. 2 A and A′) in control mice (AMPKα1−/−;
AMPKα2F/F electroporated with EGFP only). The same numbers
of axons are projecting toward the midline in AMPKα-DcKO
neurons (AMPKα1−/−; AMPKα2F/F electroporated with Cre-
IRES-EGFP plasmid) (red arrow in Fig. 2B). We also found no
difference in the distribution of neurons in control and AMPKα-
DcKO slices (Fig. S2) confirming our layer-specific marker
analysis, which suggests that AMPK catalytic activity is not re-
quired for neurogenesis or neuronal migration.
Optical isolation of single neurons using confocal microscopy
revealed that control neurons migrating through the intermediate
zone (IZ) display a thick leading process (LP; arrows in Fig. 2C)
and a long trailing process (TP; arrowhead in Fig. 2C) that become
the apical dendrite and the axon, respectively, in postmigratory
neurons that reached the CP (15, 21, 22). We did not observe any
qualitative difference in LP/apical dendrite and TP/axon forma-
tion in AMPKα-DcKO neurons (AMPKα1−/−; AMPKα2F/F elec-
troporated with Cre-IRES-EGFP plasmid) (Fig. 2D) compared
with control neurons (Fig. 2C). Quantifying the percentage of
neurons displaying a single TP/axon or either no axon or multiple
axons confirmed that AMPKα-DcKO neurons show no axon
specification defect compared with control neurons (Fig. 2E).
We also used an independent method to assess axon formation
by performing EUCE coupled with immediate dissociation and in
vitro culture for 5 div. This method allows pyramidal neurons to
polarize in vitro and subsequent analysis with single cell resolution
revealed that axons (labeled by Tau1) and dendrites (labeled with
MAP2) (Fig. S3 A–D′) polarize normally in AMPKα-DcKO
neurons (Fig. 2G) compared with control neurons (Fig. 2F). Fi-
nally, we used a pharmacological approach to inhibit AMPK
Fig. 1. AMPKα is not required for cortical neuron development in vivo. Im-
munohistochemical analysis of AMPKα-DcKO (Emx1Cre/+; AMPKα1−/−;
AMPKα2F/F) mice and control (Emx1Cre/+; AMPKα1+/+; AMPKα2F/F) littermates
P3 brain slices using layer 2–4 marker Cux1 (A, A′, E, and E′), layer 5 marker
CTIP2 (B and B′), layer 6a marker Tbr1 (F and F′), radial glial progenitor marker
nestin (I and I′) and apoptotic marker cleaved caspase 3 (J and J′), axonal
marker Tau1 (M and M′), dendritic marker MAP2 (N and N′) and DRAQ5 nu-
clear marker shows cytoarchitecture (C, C′, G, G′, K, K′, O, and O′). Arrows in J
and J′ point to a cleaved caspase 3-positive cell body. Data are representative
of four independent knockout analyses for eachgenotype. (Scale bar, 150 μm.)
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catalytic activity by incubating cortical neurons in vitro with
compound C, a nonselective but potent AMPK inhibitor (Fig. S4
B and E). Qualitative and quantitative assessments demonstrate
that compound C does not affect cortical neuron differentiation
(Fig. S4 B and E) compared with control neurons exposed to
vehicle only (DMSO; Fig. S4 A and E). Overall, our genetic and
pharmacological approaches demonstrate that AMPK catalytic
activity is not required for proper neurogenesis, neuronal migra-
tion, polarization, or survival in vivo or in vitro.
Metabolic Stress Impairs Axogenesis in Cortical Neurons. AMPK is
an important metabolic sensor required to maintain epithelial cell
polarity during metabolic stress such as nutrient deprivation and
lowering of the ATP:AMP ratio (6, 9). We wanted to test whether
various forms of metabolic stress known to activate AMPK, in-
cluding exposure to the mitochondrial inhibitor metformin—the
drug most prescribed to treat type 2 diabetes—or the stimulator
of glucose uptake, AICAR, would affect neuronal polarization.
As expected, we show that metformin and AICAR (Fig. S5) ro-
bustly activate AMPK in neurons by measuring the levels of active
phospho-AMPKα and the phosphorylation of its downstream
targets ACC and GABAB R2 after treatment. Interestingly,
treatments of E15 cortical neurons for 4 div with either metformin
or AICAR showed a dose-dependent effect on neuronal polari-
zation leading to over 85% of neurons without a Tau1 positive
axon (Fig. S3 E–L and Fig. S4 C, D, F, and G). Importantly, be-
cause >95% of cells electroporated by EUCE are radial glial
progenitors (18), these results confirm that generic steps of neu-
ronal differentiation are not affected by these treatments because
over 90% of the cells express panneuronal markers including
Tau1 and MAP2 (Figs. S3 and S4). However, in the presence of
metformin or AICAR, these neurons fail to polarize properly.
Specifically, neurons fail to form a single Tau1-positive (MAP2-
negative) axon, but instead have multiple short neurites aber-
rantly labeled by both Tau1 and MAP2 (Fig. S3). These results
demonstrate that axon formation is highly sensitive to metabolic
stress. We next tested whether these effects are mediated through
AMPK activation during neuronal polarization.
Axonal Effects of AICAR, but Not Metformin, Require AMPK. Recent
studies have reported that some of the effects of metformin are
AMPK independent (23).We therefore tested whether the effects
of AICAR and metformin on axon specification and elongation
were mediated through AMPK by exposing either control or
AMPKα-DcKO cortical neurons to AICAR or metformin in vitro
(Fig. 3). Both metformin (Fig. 3 E–H andM) and AICAR (Fig. 3
I–L and N) treatments significantly reduced the percentage of
cortical neurons successfully polarizing compared with control
(Fig. 3 A–D, M, and N). Surprisingly, the effects of metformin
were only partially mediated by AMPK activation because
AMPKα-deficient cortical neurons still show a significantly higher
proportion of neurons without Tau1-postive axon compared with
control (Fig. 3 E′–H′ and M). This is in sharp contrast with
AMPKα-deficient cortical neurons exposed to AICAR, which
show similar proportion of neurons correctly polarized with
a single axon compared with controls (Fig. 3 I′–L′ and N).
Interestingly, when we quantified the effects of metformin and
AICAR on the axon length for neurons that successfully polar-
ized, the dependence on AMPK was even more divergent (Fig.
3O). We found that axon length of AMPKα-DcKO cortical
neurons treated with metformin were not significantly longer than
wild-type neurons treated with metformin. Conversely, AMPKα-
deficient cortical neurons treated with AICAR exhibited axon
length significantly longer than wild-type neurons treated with
AICAR yet indistinguishable from vehicle-treated WT neurons
cultured in the same conditions. Overall, these results demon-
strate that unlike AICAR, which mediates its effects on axon
specification and outgrowth almost exclusively through AMPK
activation, metformin mediates some of its effects on neuronal
polarization and extension in an AMPK-independent manner
consistent with metformin AMPK-independent effects docu-
mented by others in nonneuronal cell types (24, 25).
AMPK Overactivation Inhibits Axon Formation Through Inhibition of
the mTOR Pathway. We next determined the molecular mecha-
nisms underlying the inhibition of axon formation mediated by
AMPK overactivation. Several downstream effectors have been
shown to mediate the effect of AMPK on cell polarity in different
organisms ranging from actomyosin effectors such as the acti-
vating phosphorylation of myosin light chain (MLC) (26) to the
mTOR pathway (27, 28). Interestingly, both MLC phosphoryla-
tion/myosin-II activity (29) and TSC1/2-dependent mTOR in-
activation (30) have been implicated in neuronal polarization and
axon formation. Paradoxically treatment with metformin and
AICAR did not increase the level of MLC phosphorylation on
Ser19 in cortical neurons. We therefore focused on testing the
function of the mTOR kinase pathway, which is a key regulator
of protein synthesis through the mTORC1 complex. AMPK has
been shown to directly phosphorylate TSC2 (27), an essential
Fig. 2. Axon formation is not impaired in AMPK-deficient cortical neurons.
(A–B′) The cortex of E15.5 AMPKα1−/−; AMPKα2F/F embryos were electro-
porated with EGFP alone (A and A′) or Cre-IRES-EGFP expressing vectors (B
and B′) and then maintained for 5 DEV in organotypic slice culture.
Axon projections (arrows) toward the midline (arrowheads) are identical in
AMPKα-deficient and control neurons. (Scale bar, 150 μm.) (C and D) Opti-
cally isolated EGFP-labeled neurons in control EGFP-expressing neurons (C)
or Cre-IRES-EGFP–expressing neurons (D) in the IZ or CP of slice shown in A–B′
reveal no morphological defects in AMPK-deficient neurons compared with
control. Arrows point to LP/apical dendrite and arrowheads to TP/axon.
(Scale bar, 10 μm.) (E) Quantitative morphological analysis of single neurons
reveals that more than 90% of the electroporated cells display a single TP/
axon in control (EGFP only) and AMPK-deficient (Cre-IRES-EGFP) neurons
both in the CP and IZ. Graphs represent mean percentages of three in-
dependent experiments. Error bars represent SE to the mean (SEM). (F and
G) Morphology of cortical neurons electroporated with EGFP-expressing
vector isolated from Emx1Cre/+; AMPKα1+/+; AMPKα2F/F (F) or Emx1Cre/+;
AMPKα1−/−; AMPKα2F/F (G) E15 embryos. Neurons were maintained in dis-
sociated culture for 16 div. AMPK-deficient neurons (G) do not display any
polarity defect compared with control neurons still expressing one isoform
of AMPK (F). Arrowhead points to the axon. (Scale bar, 300 μm.)
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component of the tuberin/hamartin complex that also contains
the protein TSC1. Activation of the TSC1/TSC2 complex by
AMPK enhances its inhibitory GAP activity toward Rheb
GTPase, an activator of mTOR. AMPK also exerts a second
brake on the mTOR pathway by phosphorylating raptor, a phos-
phorylation that inhibits the activity of the complex and thereby
inhibits protein synthesis. Treatment of cortical neurons in vitro
with metformin (Fig. S6) and AICAR (Fig. 4 A and B) signifi-
cantly increased the phosphorylation of AMPK (phospho-
Thr172) and raptor (phospho-Ser792), whereas mTOR (phos-
pho-Ser2448) and p70S6K (phospho-Ser371) phosphorylation
was decreased. Both treatments also resulted in the disappear-
ance of a slow migrating band corresponding to the hyper-
phosphorylated form of protein 4E-BP1 (arrow in Fig. 4A) with
increases in a faster migrating, hypophosphorylated band. These
results are compatible with previous studies and demonstrate that
in cortical neurons, AMPK activation inhibits the mTOR path-
way. Because TSC1/2 regulates neuronal polarization by inhibit-
ing axon formation (30), we tested whether AMPK overactivation
inhibits axon formation through excessive TSC1/2-mediated in-
hibition of mTOR. To do this, we performed independent TSC1
and TSC2 knockdown in the presence of AICAR. We confirmed
that knockdown of TSC2 leads to a significant increase in neurons
bearing multiple axons (Fig. 4 C–F) as previously published (30).
Most interestingly, knockdown of TSC1 and TSC2 completely
rescued the effect of AICAR treatment on axon formation (Fig. 4
C′–E′ and F) and axon growth (Fig. 4G). These results strongly
argue that AMPK overactivation inhibits axon specification and
axon growth by activating TSC1/2 and thereby inhibiting mTOR.
Discussion
Our results demonstrate unequivocally that AMPK catalytic ac-
tivity is not required for proper cortical neurogenesis, radial
migration, cortical layer formation, and axon–dendrite formation
in vivo and in vitro. Neuronal survival in the developing cortex
is also not affected by the genetic removal of all AMPKα. Our
results are in conflict with a prior study, which suggested that
AMPK is required for embryonic cortical development including
neurogenesis, neuronal survival, and differentiation (10). To
date, the large body of work suggests a dogma whereby the
AMPKβ subunit is an obligate trimer with AMPKα and AMPKγ
with effects mediated by the catalytic activity of AMPKα (5).
In part, this apparent discrepancy might be due to the nature
of the genetic allele used in the prior study. This prior study (10)
used a gene-trap allele of the regulatory subunit AMPKβ1, which
expresses a hybrid protein made of the first 224 (out of 270)
amino acids of AMPKβ1 fused in its C-terminal to β-galactosi-
dase that could generate a protein with altered function rather
than representing an AMPKβ1-null mouse model. It may be
possible that the expression of a foreign fusion protein with
a myristoylation signal (from AMPKβ1) could impair cellular
function and induce a type of nonphysiological stress that
unmasks an AMPK-dependent function. Another more straight-
forward possibility is that AMPKβ1 simply has independent
Fig. 3. Effects of AICAR but not metformin on axon specification and outgrowth are entirely mediated by AMPK. (A–L′) Cortical neurons from control
(Emx1Cre/+; AMPKα1+/+; AMPKα2F/F; A–L) or AMPKα-DcKO (Emx1Cre/+; AMPKα1−/−; AMPKα2F/F; A′–L′) animals were electroporated and dissociated at E15.5.
After 2 div, neurons were treated with either vehicle (DMSO, A/A′–D/D′), metformin (1 mM, E/E′–H/H′), or AICAR (1 mM, I/I′–L/L′) for 3 div. After fixation,
cultures were stained for EGFP, Tau1 (blue), and MAP2 (red). (M and N) Neuronal polarity was quantified for three independent experiments (≥300 neurons
for each treatment) for neurons from control animals or AMPKα-DcKO. (O) Axon length was measured using ImageJ software. Box plots representing the
10th, 25th, median, 75th, and 90th percentiles illustrate the distribution of the data. Fisher’s exact test was used to statistically analyze the data represented
in A/A′–L/L′. Statistical analysis conducted on axon length was performed using one-way ANOVA.
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functions of AMPKα despite the current dogma. Future in-
vestigation of the proteins that AMPKβ1 binds to and regulates
might resolve this discrepancy. However, a second group (31),
which recently globally disrupted AMPKβ1 by conventional loss-
of-function gene targeting, failed to find neuronal development
phenotypes and obtained viable and fertile AMPKβ1-knockout
mice. Currently, AMPKα is largely thought to mediate AMPK
catalytic activity and therefore our genetic loss-of-function data
likely reflect the role of AMPK activity in the developing nervous
system. Our results also reveal different phenotypes from LKB1
loss-of-function mutants in the same neurons, which require
LKB1 for neuronal polarization and survival in vivo (15, 16). In
other model organisms, including Drosophila, LKB1 neural phe-
notypes are always significantly more severe than AMPKα phe-
notypes (32), which could be due to the fact that LKB1 is
upstream of AMPK and at least 11 other kinases (33, 34). Our
results are consistent with such studies and we speculate that
during mammalian embryonic brain development AMPKα ac-
tivity is present but not essential for proper neural development;
however, its hyperactivation has profound consequences on early
neural development. This is largely compatible with data from
other multicellular organisms like Caenorhabditis elegans where
AMPKα is not required for normal development, but only for
surviving energetic stress paradigms (35). Our results are also
consistent with genetically null AMPKα Drosophila mutants that
specify neurons in the embryo and adult properly, which extend
axons and dendrites (6, 33).
The mTOR-dependent pathway has previously been involved in
neuronal polarization, when TSC1/2 inhibits axon specification by
repressing SAD-A/B kinases protein synthesis (29). Importantly,
our study shows that the inhibitory effects on axon formation and
growth via AMPKoveractivation require TSC1 and -2. Knockdown
of TSC1 andTSC2 results in full rescue of axon formation and axon
growth during AICAR-induced AMPK activation (Fig. S7A).
We have previously shown that, unlike in other cell types (2),
LKB1 is not the major AMPK-activating kinase in neurons be-
cause there is no significant change in T172 phosphorylation in
LKB1-deficient neurons in vivo (15). Ca2+-calmodulin–dependent
kinase kinase β (CAMKKβ) has previously been shown to phos-
phorylate T172 on AMPK in neurons and might therefore be the
relevant upstream activator of AMPK in neurons (36) (Fig. S7A).
Our results show that axogenesis and axon growth can be im-
paired during times of severe energetic stress, which potently
activates AMPK (1, 2, 6) (Fig. S7B). We were able to show in vitro
that cultured cortical neurons treated with AICAR or metformin
lead to aberrant neuronal polarization. Future investigations
Fig. 4. AMPK activation impairs axon formation through the TSC/mTOR pathway. (A) Western blot analysis after in vitro culture of E18.5 mouse cortical
neurons cultured for 1 d, then treated with AICAR (1 mM) for 3 d in vitro. Treatments increased the phosphorylation of AMPK (phospho-Thr172) and raptor
(phospho-Ser792), whereas mTOR (phospho-Ser2448) and p70S6K (phospho-Ser371) phosphorylation were decreased. Treatment also resulted in the dis-
appearance of a slow migrating band corresponding to 4E-BP1 (arrow). (B) Quantification of phospho-AMPK, phospho-raptor, phospho-mTOR, and phospho-
70S6K signal normalized to total amount of corresponding proteins compared with control condition (DMSO vehicle only). Error bars represent SEM (n = 5).
(C–E) Morphology of cortical neurons electroporated with control vector (C), or short-hairpin (sh)RNA targeting TSC1 (D), or TSC2 (E) and cultured in vitro for
4 d exposed to control vehicle only (DMSO) or the AMPK activator AICAR (1 mM). Arrowheads point to single axons. (Scale bar, 100 μm.) (F) Neuronal polarity
was quantified by determining the percentage of neurons with single axon, multiple axons, or no axon for five independent experiments (≥500 neurons for
each treatment) for neurons shown in C–E. Statistical analyses were performed using Fisher’s exact test. (G) Quantification of axon length for neurons shown
in C–E. Box plots are as in Fig. 3. Statistical analysis was performed using one-way ANOVA.
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should determine whether metabolic stress, environmental in-
sults, or other pathological situations known to activate AMPK,
could impact brain development through its ability to modulate
axon formation, axon growth, and maybe other aspects of neu-
ronal differentiation. Our results have important implications in
the context of neurodegeneration especially in light of recent
results suggesting that in Drosophila, neurodegeneration induced
by Par1 (MARK)-mediated Tau-hyperphosphorylation can be
significantly suppressed by reducing LKB1 expression (37, 38).
Future experiments should further explore the relationship be-
tween metabolic stress, AMPK activation, and axon formation,
growth, or maintenance in the context of neurodegeneration.
Materials and Methods
Animals.Mice were used according to protocols approved by the Institutional
Animal Care and Use Committee at the University of North Carolina-Chapel
Hill, The Scripps Research Institute, and in accordance with National Institutes
of Health guidelines. Time-pregnant females were maintained in a 12 h light/
dark cycle and obtained by overnight breeding with males of the same strain.
Noon following breeding is considered as E0.5.
Antibodies. See Table S1.
Constructs and Reagents. All cDNAs were subcloned into a pCIG2 vector (18),
which contains a (cDNA)-IRES-EGFP under the control of a CMV-enhancer/
chicken β-actin promoter. pCIG2:CRE has been described previously (18).
shRNA vectors targeting mouse Tsc1 and Tsc2 genes were selected from
the TRC library and purchased from Sigma-Aldrich. All chemicals were pur-
chased from Sigma excepted when indicated otherwise. Neurons were trea-
ted with the following drugs: In solution AMPK inhibitor compound C
(Calbiochem), AICAR (Toronto Research Chemicals), and metformin (Sigma).
The treatments were performed by adding the drug at the concentration
indicated in figure legends directly in the culture medium. AMPK activation/
inhibition was maintained over several days by adding to the culture medium
half of the indicated concentration every day.
RT and PCR. mRNA from mouse cortex were obtained by RNA extraction and
purificationusingNucleospinRNA II kit (MachereyNagel). RNAwas treatedwith
DNase I during the purification procedure to prevent contamination of the
samples with genomic DNA, as recommended by the manufacturer. cDNA con-
versionwasperformedwithQiagenOmniscript kit using1 μgmRNAas template
andoligodTprimers (Invitrogen).Fragmentsspecific toAMPKα1,α2,andGAPDH
were obtained using the following primers: PRKAA1_F 5′-GCTGTGGCTCACC-
CAATTAT-3′ and PRKAA1_R 5′-TGTTGTACAGGCAGCTGAGG-3′, PRKAA2_F 5′-
CGCCTCTAGTCCTCCATCAG-3′ and PRKAA2_R 5′-CAGCTGTGCTGGAATCAAAA-
3′, and GAPDH_F 5′-AACTTTGGCATTGTGGAAGG-3′ and GAPDH_R 5′-CCCTG-
TTGCTGTAGCCGTAT-3′. Thirty cycles of PCR were performed using Taq DNA
polymerase (Qiagen) at the hybridization temperature of 57.5 °C.
Western Blotting. Western blotting was performed as described previously
(18). See SI Materials and Methods for details.
Ex Utero Electroporation and Organotypic Slice Culture. EUCE was performed
as described previously (18) (SI Materials and Methods).
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